173 related articles for article (PubMed ID: 18558304)
21. Management of hypercalcemia after renal transplantation.
Torregrosa JV; Barros X
Nefrologia; 2013 Nov; 33(6):751-7. PubMed ID: 24241361
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of cinacalcet HCl treatment after kidney transplantation.
Copley JB; Germain M; Stern L; Pankewycz O; Katznelson S; Shah T; Wang O; Turner SA; Sprague SM
Transplant Proc; 2010 Sep; 42(7):2503-8. PubMed ID: 20832532
[TBL] [Abstract][Full Text] [Related]
23. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
24. Management of mineral and bone disorder in chronic kidney disease: quo vadis?
Nakai K; Komaba H; Fukagawa M
Ther Apher Dial; 2009 Oct; 13 Suppl 1():S2-6. PubMed ID: 19765254
[TBL] [Abstract][Full Text] [Related]
25. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
Tahara H
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
[TBL] [Abstract][Full Text] [Related]
26. Achieving targets for bone and mineral metabolism: the impact of cinacalcet HCl in clinical practice.
Spiegel DM; Casey L; Bell S; Parker M; Chonchol M
Hemodial Int; 2006 Oct; 10 Suppl 2():S24-7. PubMed ID: 17022747
[TBL] [Abstract][Full Text] [Related]
27. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study.
Zitt E; Rix M; Ureña Torres P; Fouque D; Jacobson SH; Pétavy F; Dehmel B; Ryba M
Nephrol Dial Transplant; 2011 Jun; 26(6):1956-61. PubMed ID: 20947534
[TBL] [Abstract][Full Text] [Related]
29. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.
Torregrosa JV; Bergua C; Martinez de Osaba MJ; Oppenheimer F; Campistol JM
Transplant Proc; 2009; 41(6):2396-8. PubMed ID: 19715931
[TBL] [Abstract][Full Text] [Related]
30. Clinical experience with cinacalcet HCl.
Ureña Torres P
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V27-33. PubMed ID: 15284357
[TBL] [Abstract][Full Text] [Related]
31. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
32. Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder.
Yokoyama K
Clin J Am Soc Nephrol; 2009 Sep; 4(9):1405-8. PubMed ID: 19696214
[No Abstract] [Full Text] [Related]
33. Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis.
Díez JJ; Miguel JL; Codoceo R; Iglesias P; Bajo MA; Sánchez C; Del Peso G; Gil F; Martinez-Ara J; Gancedo PG; Selgas R
Nephrol Dial Transplant; 2008 Apr; 23(4):1387-95. PubMed ID: 18045826
[TBL] [Abstract][Full Text] [Related]
34. [Effect of cinacalcet on parathyroid hormone level in hypercalcemic hyperparathyroidism of patients with renal transplantation].
Vaquero E; Esteban de la Rosa RJ; Oliva N; Fernández Castillo R; Fernández Gallegos R; Bravo Soto J
Med Clin (Barc); 2012 Apr; 138(8):323-6. PubMed ID: 21492884
[TBL] [Abstract][Full Text] [Related]
35. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.
Kruse AE; Eisenberger U; Frey FJ; Mohaupt MG
Nephrol Dial Transplant; 2005 Jul; 20(7):1311-4. PubMed ID: 15941846
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.
Iseki K
Expert Opin Pharmacother; 2008 Mar; 9(4):601-10. PubMed ID: 18312161
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
Nakanishi S; Fukagawa M
Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
[TBL] [Abstract][Full Text] [Related]
38. Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism.
Bergua C; Torregrosa JV; Cofán F; Oppenheimer F
Transplant Proc; 2007 Sep; 39(7):2254-5. PubMed ID: 17889155
[TBL] [Abstract][Full Text] [Related]
39. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.
Komaba H; Fukagawa M;
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S44-9. PubMed ID: 19032527
[TBL] [Abstract][Full Text] [Related]
40. Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients.
Aladrén Regidor MJ
Clin Nephrol; 2009 Feb; 71(2):207-13. PubMed ID: 19203518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
